LONDON, May 8, 2014 /PRNewswire/ --
On Wednesday, May 07, 2014, the NASDAQ Composite ended at 4,067.67, down 0.32%, the Dow Jones Industrial Average finished the day 0.72% higher at 16,518.54, and the S&P 500 closed at 1,878.21, up 0.56%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.01, up 0.23%, and the index has advanced 0.50% in the last one month. Investor-Edge has initiated coverage on the following equities: Hemispherx Biopharma Inc. (NYSE MKT: HEB), Orexigen Therapeutics Inc. (NASDAQ: OREX), Dynavax Technologies Corporation (NASDAQ: DVAX) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free technical research on HEB, OREX, DVAX and SGYP can be downloaded upon signing up at:
http://www.investor-edge.com/2275-register
Hemispherx Biopharma Inc.'s stock fell by 4.82%, to close Wednesday's session at an intra-day low of $0.32, after oscillating between $0.32 and $0.35. The stock recorded a trading volume of 1.01 million shares, below its three months average volume of 1.59 million shares. Over the last one month and previous three months, Hemispherx Biopharma Inc.'s shares have lost 14.33% and 23.40%, respectively. However, from the beginning of 2014, the company's stock has advanced 21.40%. The stock is trading above its 200-day moving average. The company stock's 50-day moving average of $0.38 is above its 200-day moving average of $0.30. Further, the company's stock has a Relative Strength Index (RSI) of 46.05. Sign up today to read free research on HEB at:
http://www.investor-edge.com/2275-HEB-08May2014.pdf
Shares in Orexigen Therapeutics Inc. recorded a trading volume of 2.10 million shares on Wednesday, which was close to its three months average volume of 2.20 million shares. The stock finished the day at $5.44, down 0.73%, and registered an intraday range of $5.25 and $5.53. Shares in Orexigen Therapeutics Inc. have declined 4.39% in the last one month and 3.37% on YTD basis. Furthermore, the company's stock is trading below its 50-day and 200-day moving averages of $6.32 and $6.30, respectively. Additionally, shares of the company have an RSI of 43.36. Sign up today to read free research on OREX at:
http://www.investor-edge.com/2275-OREX-08May2014.pdf
On Wednesday, Dynavax Technologies Corp.'s stock finished the session 1.37% higher at $1.48. A total of 2.25 million shares were traded, which was below its three months average volume of 3.29 million shares. The stock moved between $1.39 and $1.50 during the session. Over the last one month and previous three months, Dynavax Technologies Corp.'s shares have declined 7.79% and 14.45%, respectively. Also, the stock has gone-down by 24.49% since the start of this year. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $1.72 is greater than its 200-day moving average of $1.55. Dynavax Technologies Corp.'s stock has an RSI of 40.05. Sign up today to read free research on DVAX at:
http://www.investor-edge.com/2275-DVAX-08May2014.pdf
Shares in Synergy Pharmaceuticals Inc. fluctuated between $3.92 and $4.30 before ending the session down 2.17%, at $4.05. The company's stock reported a trading volume of 1.40 million shares on Wednesday, which was at par with its three months average volume. Further, Synergy Pharmaceuticals Inc.'s shares have lost 10.20% over the last one month and 20.38% over the previous three months. Also, the stock has fallen by 27.03% on YTD basis. The stock is trading below its 50-day and 200-day moving averages. The stock's 50-day moving average of $5.26 is greater than its 200-day moving average of $4.79. Moreover, shares of the company have an RSI of 37.12. Sign up today to read free research on SGYP at:
http://www.investor-edge.com/2275-SGYP-08May2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Investor-Edge
